Background Subcutaneous administration of the monoclonal antibody L9LS protected adults
against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal …

Background New approaches for the prevention and elimination of malaria, a leading cause
of illness and death among infants and young children globally, are needed. Methods We …

Background CIS43LS is a monoclonal antibody that was shown to protect against controlled
Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody …

Background Additional interventions are needed to reduce the morbidity and mortality
caused by malaria. Methods We conducted a two-part, phase 1 clinical trial to assess the …

Background Human monoclonal antibodies might offer an important new approach to
reduce malaria morbidity and mortality. In the first two parts of a three-part clinical trial, the …

Background Malaria elimination requires interruption of the highly efficient transmission of
Plasmodium parasites by mosquitoes. TB31F is a humanised monoclonal antibody that …

Transmission-blocking vaccines (TBVs) that target sexual stage parasite development could
be an integral part of measures for malaria elimination. Pfs25 is a leading TBV candidate …

Summary Background Pfs25H-EPA is a protein-protein conjugate transmission-blocking
vaccine against Plasmodium falciparum that is safe and induces functional antibodies in …

Background The candidate malaria vaccine RTS, S/AS01 is being evaluated in order to
inform a decision regarding its inclusion in routine vaccination schedules. Methods We …

Background Previous efficacy trials of SPf66 malaria vaccine have produced conflicting
results in different populations. We report a randomised double-blind trial of the SPf66 …